Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03957551 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
A Phase 1 study, sponsored by John Rieth.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03957551 is a Phase 1 study that was terminated before completion, run by John Rieth. The registered enrollment target is 28 participants.
The verdict
NCT03957551, a Phase 1 study, was terminated before completion, sponsored by John Rieth.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
Interventions
- DRUG Pembrolizumab
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-08-27 |
| Est. Completion | 2025-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03957551
The ClinicalTrials.gov registry entry for NCT03957551 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Rieth, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03957551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03957551 about?
NCT03957551 is a clinical study titled "Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma". The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
What is the current status of trial NCT03957551?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-08-27. Estimated completion is 2025-10-17.
What interventions are being tested in trial NCT03957551?
The interventions under investigation include: Pembrolizumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03957551?
This trial is sponsored by John Rieth, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.